INTRODUCTION

Top Abstract Introduction Materials and Methods Results Discussion References

The mouse virus-like 30S RNA (VL30m) elements constitute a family of retrotransposons, present at 100 to 200 copies, dispersed in the mouse genome (25, 27, 46). A typical element is 5 to 6 kb in length and contains long terminal repeats (LTRs) of about 500 nucleotides (nt) with an organization resembling that of retroviral LTRs, namely U3-R-U5 (16, 27, 37, 47). The major 30S VL30 RNA transcript is expressed at high levels and in a variety of cell types (10, 16, 22, 34). VL30m elements do not encode virus-like proteins, have little sequence homology to Moloney murine leukemia virus (MoMLV) and have not been implicated in retroviral carcinogenesis (16, 27). However, VL30 RNA possesses the unusual property of being packaged into MLV particles that are propagated in cell culture (17, 19, 33, 34, 67, 78, 79). As a consequence, VL30 elements are able to retrotranspose from cell to cell at high frequency via MLV particles (17, 27).

Packaging of viral RNA is an essential process of retroviral assembly (75). Selection of viral RNA during assembly is governed by interactions between the nucleocapsid (NC) domain of gag and the packaging signal in the viral RNA (24, 75). Packaging signals have been identified in many retroviruses, and in most, if not all, known packaging signals, major determinants are located in the 5' leader of the viral RNA between the primer binding sites and gag (75). The specificity of genomic RNA recognition and the ability of VL30m RNA to be packaged in type C retroviral particles prompted us to examine whether the 5' region of VL30m could replace functions known to be directed by the 5' leader of MoMLV (23).

An interesting feature of the MoMLV, Friend murine leukemia virus (FrMLV), Harvey murine sarcoma virus (HaMSV), and avian reticuloendotheliosis virus type A (REV-A) 5' leaders is the presence of an internal ribosome entry segment (IRES), which is able to drive translation of the Gag polyprotein in a cap-independent fashion (7, 8, 54, 87). Moreover, in FrMLV, HaMSV, and MoMLV, the IRES was found to be within the packaging signal (7, 8, 23, 87). Therefore, in spite of the fact that no translated VL30 gene products have been identified to date, it was tempting to speculate that VL30m might also have conserved a functional IRES.

Translation initiation is a multistep biochemical pathway aimed at positioning the ribosome at the initiator AUG codon of the mRNA (for a review, see reference 66). In eukaryotes, translation initiation usually takes place by a mechanism dependent on the cap structure at the 5' end of the mRNA but in certain cases has been shown to proceed in a cap-independent fashion (66, 76). Cap-dependent initiation involves attachment of the initiator methionine tRNA (Met-tRNAi) to the 40S ribosomal subunit, binding of this initiation complex to the 5' m7GpppG cap structure of the mRNA, and migration of the initiation complex along the mRNA in a 5'3' direction until the appropriate AUG codon is encountered to initiate protein synthesis (49). Cap-independent initiation (internal initiation) is mediated by a segment of secondary structure located within the 5' untranslated region of certain mRNAs, the IRES, which is able to directly recruit the 43S initiation complex (40, 57, 76). Putative IRESes can be functionally discriminated from other 5' mRNA secondary structures by their ability to mediate translation of the downstream open reading frame (ORF) of a bicistronic reporter mRNA, independent of the translational status of the first ORF (42, 44, 70).

Internal initiation was described first in poliovirus and subsequently in cardiovirus, aphthovirus, rhinovirus, and hepatitis A virus (14, 40, 41, 43, 44, 69). IRESes were later found in other types of viruses, including hepatitis C virus, bovine viral diarrhea virus, and members of the Retroviridae family (4, 7, 8, 39, 54, 85, 87). Cap-independent initiation has also been observed in cellular mRNAs encoding the immunoglobulin heavy-chain binding protein (55), human fibroblast growth factor 2 (86), human insulin-like growth factor (83), translational initiation factor eIF4G (28), platelet-derived growth factor (9), c-myc (61, 82), vascular endothelial growth factor (3, 35, 81), the products of the Drosophila homeotic genes antennapedia and ultrabithorax (63), yeast transcription factors TFIID and HAP4 (36), and the Kv1.4 voltage-gated potassium channel (62).

Based on the criteria of secondary-structure homology between VL30m and MoMLV and sequence homology between VL30m and rat VL30 (38, 48), different regions downstream of the mouse VL30 primer binding site were chosen as putative packaging sequences, and their abilities to replace the MLV 5' leader in a recombinant construct were examined. Here, we show that the 5' region of the mouse VL30 retrotransposon can direct packaging of a recombinant RNA and that it contains a functional IRES that is able to promote translation of a downstream ORF in a bicistronic RNA construct. These observations allowed the development of novel retrotransposon-based dicistronic retroviral vectors.

	MATERIALS AND METHODS

Top Abstract Introduction Materials and Methods Results Discussion References

Plasmid DNA construction and amplification. Standard procedures were used for restriction nuclease digestion and plasmid DNA construction (77). Escherichia coli HB101 strain 1035 (a recA mutant) was used for plasmid DNA amplification. Details of the constructions are given below.

DNA constructs. In all cases, nucleotide numbering is with respect to the genomic RNA cap site (position +1).

(i) pKT403. This plasmid contains the mouse VL30 1.9-kb HindIII fragment in pSP64 (NLV-3; kindly provided by S. Adams) (2).

(ii) pVL30m bicistronic RNAs. The different VL30 DNA fragments (positions 362 to 1144, 362 to 461, 362 to 575, 576 to 1144, and 462 to 1144) were generated by PCR, digested with NheI, and inserted between the neomycin phosphotransferase gene (neo) and the lacZ gene of NheI-digested pMLV-CB28 (7). The neo-VL30-lacZ sequences are under the control of the T7 RNA polymerase promoter for in vitro expression and the cytomegalovirus early promoter for expression in eukaryotic cells. In these constructs, the initiation of -galactosidase (-Gal) translation was from an AUG codon in a favorable context (GCCAUGG) which was generated by PCR (49). pEMCV-CBD260-837 was used as a positive control, while pEMCV-D837-260, containing the same encephalomyocarditis virus (EMCV) IRES fragment but in the reverse orientation, was the negative control (8).

Retroviral vectors. Retroviral vectors were prepared with pBR322 as the DNA backbone.

(i) pVL30m-SJE1. The VL30 DNA (positions 362 to 575) generated by PCR (pKT403 template) was digested with BalI and NcoI and cloned into BalI (cutting at position 800)- and NcoI (cutting at position 3449)-digested pLNPOZ (1) containing the lacZ gene and the two MLV LTRs. -Gal expression was promoted by an AUG codon in a favorable context as for pVLD362-575.

(ii) pVL30m-SJE2. The VL30 DNA (positions 362 to 1149) generated by PCR was digested with BalI and NcoI and cloned into pLNPOZ as described for pVLEL362-575.

(iii) pVL-SJE3. The oligonucleotide CCAGCTGAAGCTTGCC was cloned into pLNPOZ which had been digested with BalI (which cuts at position 800) and NcoI (which cuts at position 3449). In this construct, which served as a negative control for RNA packaging, -Gal expression was promoted by an AUG codon in a favorable context (GCCAUGG), generated by PCR.

(iv) pMLV-LacZ+. The two LTRs of pMLVK and the MLV Psi⁺ packaging sequence to position +1035 (5) were inserted into pBluescript KS. The fragment of pCH110 (Pharmacia) containing the lacZ gene was also inserted into this construct. -Gal expression was promoted by an AUG codon in a favorable context. This plasmid served as a positive control for RNA packaging into MLV virions.

(v) pVL30m-SU8. VL30 DNA (positions 362 to 575) was generated by PCR, digested with NheI, and cloned between the human placental alkaline phosphatase (PLAP) gene and neo of pMLV-CB71 (7).

(vi) pVL30m-SU9. VL30 DNA (positions 362 to 1149) was generated by PCR, digested with NheI, and cloned between the PLAP gene and neo of pMLV-CB71 (7).

(vii) pVL30m-SU11. The EcoRI fragment of pEMCV-CBT4 (83) containing the MLV 5' LTR and MLV E+ packaging sequence was cloned into pVL30m-SU9/EcoRI.

(viii) pVL30m-SU12. VL30 DNA (positions 362 to 1149) was generated by PCR, digested with EcoRI, and cloned 5' of the PLAP gene in pVL-CBT2, which contains rat VL30 between the PLAP gene and neo (8). pEMCV-CBT4 was used as an EMCV-positive control (86). pRev-HW3, containing MoMLV and REV-A IRESes, was described by López-Lastra et al. (54).

In vitro RNA synthesis. Capped and uncapped RNAs were synthesized by using a DNA template and T7 RNA polymerase (mMessage mMachine or MEGAscript; Ambion) according to the manufacturer's protocol. Plasmid DNA (1 to 2 µg) digested with SspI (which cuts at position 1240, in the lacZ gene) was used for RNA synthesis in a 20-µl final reaction volume. Transcription was terminated by digestion of the template DNA with DNase I, and RNA was precipitated with lithium chloride. RNA was resuspended in 50 µl of Tris-EDTA buffer and further purified and desalted by application to MicroSpin S-300 columns (Pharmacia Biotech) according to the manufacturer's protocol. The integrity of RNAs was monitored by 0.7% agarose gel electrophoresis, and RNA concentrations were determined spectrophotometrically.

Translation in a nuclease-treated rabbit reticulocyte lysate (RRL) system. Capped and uncapped RNAs were translated in the Flex-RRL system (Promega) at 50% concentration with 25 µg of RNA/ml and 0.6 mCi of [³⁵S]methionine (Amersham)/ml at 31°C for 1 h. The assay mixture was supplemented with potassium chloride to a final concentration of 80 mM. For EMCV RNA, 0.5 mM magnesium acetate was added. The effect of foot-and-mouth disease virus (FMDV) leader (L) protease on translation of the capped bicistronic RNAs was assayed as previously described. Briefly, the Flexi-RRL was pretreated with 1.2 µg of purified recombinant L protease (kindly provided by S. J. Morley, Department of Biochemistry, The University of Sussex, Brighton, Sussex, United Kingdom)/ml (64). After translation, samples were heated at 96°C for 3 min in a solution containing 62.5 mM Tris-HCl (pH 6.8), 2% sodium dodecyl sulfate (SDS), 10% glycerol, 5% -mercaptoethanol, and 0.02% bromophenol blue, and labelled proteins were analyzed by SDS-15% polyacrylamide gel electrophoresis (PAGE). Bands were quantified by using a PhosphorImager (Molecular Dynamics).

Cell culture. Murine NIH 3T3 cells and the ecotropic packaging cell line GP+E-86 (56) were cultured in Dulbecco's modified Eagle's medium (Gibco BRL) with 10% newborn calf serum at 37°C in a 5% CO₂ atmosphere.

Transfection, infection, and titration. Ecotropic GPE-86 cells were seeded at a density of 5 × 10⁵ per 100-mm-diameter plate 24 h prior to transfection with 20 µg of DNA by the calcium phosphate method (21). Infection and titration were performed by adding virus-containing medium to cells. NIH 3T3 cells were seeded at a density of 5 × 10⁵ per 100-mm-diameter plate 24 h prior to infection or at 2 × 10⁴ cells per well in a 24-well plate for titrations. Freshly harvested viruses were filtered (0.45-mm-pore-size filter). Diluted virus-containing supernatants were overlaid on cells in the presence of Polybrene, added to a concentration of 8 mg/ml. Cells were then incubated for 24 h, after which the medium was replaced. Infected cells were grown for a total of 48 h and either subjected to G418 selection at 1 mg/ml or stained for determination of levels of -Gal or PLAP expression. After 2 months of selection, the G418 concentration was increased to 1.5 mg/ml. The recombinant-virus titer was determined by counting the number of LacZ- or PLAP-positive NIH 3T3 cells 48 h postinfection in limiting-dilution infections. Titers, in transducing units (TU) per milliliter, were calculated as follows: (number of colonies) × (dilution of infecting retrovirus)/(total volume [in milliliters] of diluted vector overlaid on cells).

Histochemical staining. Cells were fixed in phosphate-buffered saline (PBS) containing 2% formaldehyde and 0.2% glutaraldehyde. For LacZ staining, after two washes in PBS, cells were stained with 5-bromo-4-chloro-3-indolyl--D-galactopyranoside (X-Gal). For PLAP histochemical staining, after two washes in PBS, cells were incubated at 65°C for 30 min in 1× PBS. Cells were washed twice with AP buffer (100 mM Tris-HCl [pH 9.5], 100 mM NaCl, and 50 mM MgCl₂ in double-distilled water) and stained with 0.1-mg/ml 5-bromo-4-chloro-3-indolylphosphate (BCIP), 1-mg/ml nitroblue tetrazolium salt, and 1 mM levamisole in 1× AP buffer.

Enzymatic activities. Cell extracts were used as substrates for subsequent enzymatic assays. Cells were washed twice with cold 1× PBS, scraped from plates by using a rubber policeman, collected by centrifugation at 600 × g, and resuspended in NP-40 buffer (0.5% NP-40, 140 mM NaCl, 30 mM Tris-HCl [pH 7.5]). Nuclei were removed by a 10-min centrifugation at 14,000 × g. Protein concentrations were determined by using the Micro BCA* protein assay reagent (Pierce). PLAP activity in cell extracts was determined spectrophotometrically (alkaline phosphatase substrate kit; Bio-Rad), using commercial calf intestine alkaline phosphatase (Boehringer Mannheim) as an activity standard. Neomycin phosphotransferase activity was determined by measuring [-³²P]ATP phosphate transfer to neomycin as previously described (73).

Western blotting. Cells were washed twice with PBS, trypsinized, and collected by centrifugation at 600 × g. Cells were directly resuspended in NP-40 buffer; this was followed by a 10-min centrifugation at 14,000 × g. The supernatant was transferred to a new tube, and the protein concentration was determined by using the Micro BCA* protein assay reagent (Pierce). Once quantified, 10 µg of total protein was subjected to SDS-15% PAGE. Proteins were transferred to a polyvinylidene difluoride membrane (Boehringer Mannheim) by semidry transfer in a 30% methanol-Tris-glycine buffer. The filter was blocked with 5% fat-free dried milk in TBST (10 mM Tris-HCl [pH 7.4], 150 mM NaCl, and 0.05% Tween 20). The membrane was incubated for 1 h at room temperature in a 1:800 dilution of rabbit anti-neomycin phosphotransferase II antibody (5 Prime3Prime, Inc.) in blocking buffer; after two 15-min washes in TBST, the membrane was incubated as before in a 1:800 dilution of biotinylated anti-rabbit immunoglobulin G antibody (BioSys; BIOSYS S.A., Compiègne, France). After two washes with TBST, the membrane was incubated for 30 min in VECTRASTAIN Elite ABC avidin-peroxidase solution (Vector Laboratories) and developed by enhanced chemiluminescence (ECL; Amersham) according to the manufacturer's protocol.

Effect of rapamycin on protein synthesis in murine cells. Stably transduced NIH 3T3 cells were grown to 70 to 80% confluency. Cells were serum starved for 48 h prior to the addition of Dulbecco's modified Eagle's medium containing 10% newborn calf serum and either 50 ng of rapamycin (Sigma)/ml or vehicle alone. Four hours after serum stimulation, protein extracts were prepared (see previous section). As previously described (54), the level of reporter gene expression, determined by measuring enzymatic activity in the presence and in the absence of rapamycin, was used to calculate the effect of the drug as a percentage increase or decrease relative to untreated cells.

	RESULTS

Top Abstract Introduction Materials and Methods Results Discussion References

Recombinant MLV-VL30m vectors allow expression of LacZ in transduced NIH 3T3 cells. To evaluate whether the 5' region of VL30m can replace the 5' leader of MoMLV in a recombinant construct, two regions downstream of the VL30m primer binding site were chosen as putative packaging sequences. These regions were placed upstream of lacZ in a monocistronic MLV-based retroviral vector (Fig. 1A). pMLV-LacZ+, containing the MLV E+ packaging sequence, was used as a positive control, while pVL-SJE3, containing a random sequence in place of a packaging signal, was used as a negative control. Vectors were transfected into GP+E-86 cells, and virus-containing medium was later recovered and used to transduce NIH 3T3 cells. The number of NIH 3T3 LacZ-positive cells obtained after transduction with vectors pVL30m-SJE1 and pVL30m-SJE2 was of the same order of magnitude as that for pMLV-LacZ+, the control vector (data not shown). This preliminary observation prompted us to determine the recombinant-virus titer of the stably producing helper cell line, set up by cotransfecting GP+E-86 cells with pSV2neo and the different vector constructs (80). As shown in Table 1, upon G418 selection, the titers obtained with the MLV-VL30m vectors were of the same order of magnitude as those of the control MLV vector. These data not only confirm the work of Chakraborty et al. (20), which suggested that the 5' region of VL30m has the ability to drive packaging of a recombinant RNA, but because LacZ is expressed, they also show that VL30m can direct translation of a 3' cistron in the context of a monocistronic retroviral vector.

View larger version (23K): [in this window] [in a new window]   FIG. 1.   Schematic representation of MLV-VL30m-lacZ monocistronic retroviral vectors. All MLV-VL30m vectors contain the 5' LTR and the primer binding site of MLV. In vectors pVL30m-SJ E1 and pVL30m-SJ E2, different segments of the 5' region of NLV-3 VL30 sequences were inserted upstream of the lacZ reporter cistron. The pMLV-LacZ+ vector, used as a positive control, contains the MLV Psi+ encapsidation sequence. pVL-SJE3, used as a negative control, contains no encapsidation sequence. Numbering is with respect to the VL30m RNA cap site (position +1).

The 5' region of VL30m directs expression of a 3' cistron of a bicistronic RNA in RRL. Based on published data for MoMLV (87), HaMSV (8), FrMLV (7), and REV-A (54), we hypothesized that VL30m contains a functional IRES. As a first approach in the characterization of the putative VL30m IRES, capped and uncapped monocistronic RNAs, with different segments of VL30m 5' RNA upstream from lacZ, were translated in an RRL system. Results suggested that translation of RNAs containing VL30m 5' sequence proceeded independently of the cap (data not shown). These data prompted us to test the translational ability of these sequences when contained within a bicistronic mRNA (Fig. 2A) (42, 44, 70). In pVL30m bicistronic RNAs, the VL30m sequences from position 362 to 1144, 362 to 461, 362 to 575, 576 to 1144, or 462 to 1144 were inserted between neo and the lacZ gene, as previously described (Fig. 2A) (54). In all constructs, the first cistron lies downstream of a short 5' capped or uncapped untranslated region (54 nt), and the 3' cistron (lacZ) would be expressed only if the VL30m sequence has IRES activity or through a termination reinitiation mechanism (42, 66, 70). As a positive control for cap-independent translation, we used pEMCV-CBD260-837 RNA (Fig. 2A), containing the EMCV IRES, while pEMCV-D837-260, with the complete EMCV leader in the reverse orientation, was used as a negative control.

View larger version (32K): [in this window] [in a new window]   FIG. 2.   Translation of VL30m bicistronic RNA in messenger-dependent RRL. (A) Schematic representation of the bicistronic plasmid constructs containing different portions of the VL30 5' RNA located between the neo and lacZ genes under the control of the T7 promoter (Po T7) for in vitro expression. Numbering is with respect to the genomic RNA cap site (position +1). Po CMV, cytomegalovirus early promoter; KD, kilodaltons. (B) Translation of uncapped () and capped (+) bicistronic RNA in the Flexi-RRL system (Promega). After heat denaturation, 35S-labelled proteins were analyzed by SDS-15% PAGE. The positions of neomycin phosphotransferase (28 kDa) and the C-terminally truncated -Gal protein (46 kDa) are indicated. Lanes 1 to 4, control RNAs containing the EMCV IRES (see Materials and Methods); lanes 7 to 10 RNAs containing different 3' deletions in the putative VL30m IRES; lanes 5, 6, and 11 to 14, RNAs containing the 5' region VL30m RNA or 5' deletions of this sequence.

Influence of FMDV L protease on in vitro translation of bicistronic VL30m RNAs. We next examined the effect of the L protease of FMDV on VL30m bicistronic RNA translation (Fig. 3; Table 2). Translation of capped RNA is disrupted when the initiation factor eIF4G is cleaved by viral proteases such as 2A of poliovirus, coxsackievirus, and human rhinovirus or the L protease of FMDV (11, 65, 89, 90). Previous studies using L protease-treated RRL revealed the ability of this protease to partially inhibit translation of capped cellular RNA while internal initiation remained unaffected (54, 64, 65). When capped VL30m bicistronic RNAs or capped pEMCV-CBD260-837 (Fig. 2A) was translated in L protease-treated RRL, the level of -Gal synthesis was enhanced whereas the level of neomysin phosphotransferase expression decreased (Fig. 3, lanes 1 and 2 [for EMCV] and lanes 9 to 12 [for VL30m]). In confirmation of data presented in Fig. 2B (lanes 8 and 10), -Gal was poorly expressed by capped pVL30m 362-461 and pVL30m 362-575 RNAs (Fig. 3, lanes 5 and 7). However, when cap-dependent translation was inhibited by L protease, translation from the 3' cistron was partially restored (Fig. 3; compare lanes 5 and 6 and lanes 7 and 8). This confirms that the 3' region of the VL30m 5' sequences is important for optimal IRES activity (Fig. 3, lanes 5 to 8). The effect of L protease on expression of neomycin phosphotransferase and -Gal was quantitated by scanning densitometry, and data are summarized in Table 2. The contrasting effect of L protease on the synthesis of neomycin phosphotransferase and LacZ is in agreement with previously published data (32, 54, 64, 65, 89, 90) and confirms the presence of a functional IRES within the 5' region of VL30m RNA. Our in vitro assays showed that cap is able to shut down IRES activity from RNA pVL30m 362-575, an effect that can be abolished by treatment with FMDV L protease (Fig. 2B, lanes 7 and 8; Fig. 3, lanes 5 and 6). It should also be pointed out that ex vivo (Fig. 1; Table 1), monocistronic retroviral vector pVL30m-SJ E1, containing the 5' VL30m region from nt 362 to 575, was able to promote synthesis of -Gal in murine cells.

View larger version (46K): [in this window] [in a new window]   FIG. 3.   Effect of FMDV L protease on bicistronic-RNA translation. Bicistronic capped RNA was translated in the Flexi-RRL system (Promega) with (+) or without () L protease (PL). After heat denaturation, 35S-labelled proteins were analyzed by SDS-15% PAGE. The positions of neomycin phosphotransferase (28 kDa) and the C-terminally truncated -Gal protein (46 kDa) are indicated. Lanes 1 and 2, control RNAs containing the EMCV IRES (see Materials and Methods); lanes 5 to 8, RNAs containing different 3' deletions in the putative VL30m IRES; lanes 3, 4, and 9 to 12, RNAs containing the 5' region VL30m RNA or 5' deletions of this sequence.

Construction of MLV-based bicistronic retroviral vectors, using the 5' region of VL30m. Retroviral vectors incorporating mouse VL30 sequences have been proposed to have potential use in gene therapy (18, 20, 26). To evaluate the use of VL30m 5' region (E/IRES) in gene transfer and to test its function in cells, we constructed bicistronic retroviral vectors.

View larger version (24K): [in this window] [in a new window]   FIG. 4.   Schematic representation of the bicistronic retroviral vectors. The VL30m-MLV-based retroviral vectors are built on a pBR322 backbone. VL30m corresponds to the 5' RNA region of the mouse VL30 retrotransposon, VL30r corresponds to the 5' untranslated region of HaMSV (8), and MLV E+ corresponds to the extended packaging region of MLV (5). Placental alkaline phosphatase (plap) and neomycin phosphotransferase (neo) were used as marker genes. The control vectors pEMCV-CBT4 and pRev-HW3 possess two IRESes (53, 84), the first from MLV (7, 87), which also directs packaging (E+), and the second from EMCV or REV-A (53). In all cases, numbering is with respect to the genomic RNA cap site (position +1).

View larger version (27K): [in this window] [in a new window]   FIG. 5.   Monitoring double transgene expression. Proteins extracted from transduced PLAP-positive neomycin-resistant NIH 3T3 cells were used to determine the level of expression of each transgene by vector constructs. (A) PLAP enzymatic activities were determined as described in Materials and Methods (53, 84). The mean values of alkaline phosphatase specific activities as well as the standard deviation for each set of experiments are shown. Data are the averages of values from three independent experiments. (B) Ten micrograms of total protein was loaded per lane and subjected to SDS-15% PAGE. Proteins were transferred to a polyvinylidene difluoride membrane and probed with a rabbit anti-neomycin phosphotransferase II antibody. The membrane was then incubated with a biotinylated anti-rabbit immunoglobulin G antibody and an avidin-peroxidase solution and, finally, developed by enhanced chemiluminescence. Lane 1, negative control (protein extract from nontransduced NIH 3T3 cells); lanes 2 through 6, protein extracts from cells transduced with the different retroviral vectors. The positions of molecular mass standards are shown on the left.

	DISCUSSION

Top Abstract Introduction Materials and Methods Results Discussion References

A characteristic feature of VL30 retrotransposons is that they can be packaged into MLV virions, leading to their horizontal spread during retrovirus dissemination (17, 19, 33, 34, 67, 78, 79). Based on this observation, we asked whether the 5' region of VL30m RNA could replace the MLV E+ sequence functionally in a recombinant viral RNA. For this, monocistronic vectors were constructed in which the MLV E+ packaging sequence was replaced by the 5' region of VL30m. Upon transfection of GP+E-86 helper cells, the packaging potential of the 5' region of VL30m RNA was determined by titrating the recombinant lacZ vectors. These initial experiments showed that the 5' region of VL30m RNA can indeed replace the E sequence of MoMLV in a recombinant retroviral construct (Fig. 1; Table 1). Moreover, and contrary to what is predicted by the scanning model of translation initiation, the length and secondary structure of the VL30m 5' region did not prevent lacZ expression (50-52). This prompted us to determine the mechanism of translation initiation of VL30m 5' RNA. Since the leaders of MoMLV (87), HaMSV (7), FrMLV (7), and REV-A (54) genomic RNAs have each been described as containing an IRES, we hypothesized that VL30m RNA also has an IRES.

To characterize the VL30m IRES, we used the canonical strategy of bicistronic constructs, first described by Pelletier and Sonenberg (70) and Jang et al. (44) (Fig. 2). The results, presented in Fig. 2B, show that the VL30m 5' region allows translation of the downstream cistron in a bicistronic construct independently from that of the first cistron (Fig. 2). Moreover, FMDV L protease, which is known to specifically shut off cap-dependent translation initiation, enhanced translation initiation driven by the VL30m 5' region while reducing expression of neo, the cap-dependent gene (Fig. 3). These data suggest that as for other IRESes, the cap binding protein of the translation preinitiation complex, eIF4E, may not be required for VL30m-driven translation initiation (65, 71). This idea was further sustained by the results obtained with capped RNAs pVL30m 362-461 and pVL30m 362-575, for which a 3' deletion was able to impair translation of the 3' cistron. In addition, when cap-dependent translation initiation was inhibited by L protease, translation of the 3' cistron was enhanced. Together, these data confirm that the 5' region of VL30m is able to drive translation initiation independently of the 5' cistron; therefore, this region is capable of recruiting ribosomes by an internal mechanism. The decrease in translation of RNAs pVL30m 362-461 and pVL30m 362-575 as well as the increase in cap-independent translation in the presence of L protease is most probably due to an active competition between the 5' cap structure and the IRES for the recruitment of canonical translation initiation factors (71, 72, 89, 90).

To confirm the data in a cellular context, a series of retroviral vectors containing the 5' region of VL30m RNA has been constructed. Retroviral vectors not only allow testing of the functionality of IRESes ex vivo but also permit their exploitation in gene transfer and therapy. In this respect, IRESes represent an efficient means of expressing two transgenes in cells without the need for two promoters or a regulated splicing mechanism (1, 29, 30, 54, 58, 60, 76, 84). In MLV-based vectors, the packaging signal comprising the extended (E+) region of MLV encompasses sequences encoding Gag and glyco-Gag. These sequences, which might be the cause of homologous recombinations possibly generating replication-competent retroviruses, cannot be deleted without destroying the ability of the recombinant RNA to be encapsidated into virions. Our results show that the VL30 5' region is capable of directing both packaging (Fig. 1 and Table 1) and transgene expression (Fig. 2 and 3 and Table 2). We therefore constructed novel MLV-VL30 vectors (Fig. 4) to determine whether the VL30m E/IRES characterized in vitro could be used in the development of bicistronic vectors.

Upon transduction of murine cells, the VL30m IRES was found to be functional, since it allowed expression of a 3' cistron of a bicistronic retroviral vector. Moreover, by combining VL30m and rat VL30, we were able to develop an efficient IRES-based vector, pVL30-SU12, that contains only the LTRs of MLV, thus reducing to a minimum the sequences that can potentially recombine with those encoding Gag and glyco-Gag. This improvement, together with those of others (18, 20, 26), will allow the development of safer retrotransposon-based vectors that are less likely to undergo homologous recombination.

Several lines of evidence, such as sequence analysis indicating that the VL30m 5' region contains stop codons in all reading frames (2), suggest that VL30m has no translational activity. This is supported by the fact that to date no VL30m-encoded polypeptides have been identified (27). Nevertheless, there exist numerous blocks of amino acid homology between VL30 and retroviral genes, suggesting that VL30m RNA contains the remnants of ancestral gag and pol genes (2). This, together with the presence of an IRES, might reflect an ancient translational activity, which could explain why VL30m RNA has been found associated with polyribosomes (25, 45). Moreover, it should be pointed out that in Mus dunni endogenous virus, which appears to be a chimera between VL30m and a virus similar to gibbon ape leukemia virus, genomic RNA packaging and Gag polyprotein expression are most probably driven by the VL30m 5' region herein reported to contain a functional IRES (88).

It is tempting to speculate about the conservation of these retroviral IRESes. Due to the compact size of retrotransposon genomes, it is not surprising that the long 5' region participates in multiple transposon life cycle functions. It is clear that higher-order RNA structures can persist through evolution despite substantial changes in primary nucleotide sequence. Thus, it is a distinct possibility that as for MoMLV, FrMLV, and HaMSV, the VL30m IRES is contained within the region which determines dimerization and subsequent packaging of its RNA. Hence, its maintenance would be required for the preservation of the retrotransposon. To date, no specific biological role has been described for the VL30m retrotransposon. VL30s, despite their close association with oncogenic MLVs, have not been directly linked to oncogene activation (27). Since mouse VL30 sequences are actively transcribed under a variety of stimuli, they might act as insertional mutagens via gene activation, as with murine retroviruses (27). On the other hand, the variety of VL30 LTR promoters found in the mouse, together with their mobility, may also provide possible mechanisms for evolutionary changes in gene regulation as well as for the spread of genes across species (15). Although the data presented herein do not allow us to directly address the question of the biological role of this family of retroelements, they do support the hypothesis that VL30m not only activates genes at the level of transcription but also has an effect on translation due to its IRES activity.